🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

New/updated AUA guideline on screening and diagnosis of PrCa Led by ⁦Daniel Lin⁩ and ⁦John Wei⁩ Early Detection of Prostate Cancer: AUA/SUO Guideline (2023) - American Urological Association auanet.org/guidelines-and…

Ab#262 ASCO #GU24 #HariT.👉tinyurl.com/3yk3ers7👉Stockholm 3 blood test vs PSA testing in SEPTA trial for #prostatecancer 👉 superior specificity vs PSA test ➡️avoid unnecessary bx👇Dr. Adam Murphy OncoAlert UroToday.com PCF Science Uromigos

Great to see the Stockholm3 SEPTA trial presented at #GU24! A racially diverse validation and a huge team effort meetings.asco.org/abstracts-pres… Tobias Nordström Nathan Perlis Michael Abern Scott Eggener Kara Watts Alex Chow, MD Thorgerdur Palsdottir Michael Liss Dr Andre Abreu Geoffrey A. Sonn, MD Dr. Adam Murphy

#Stockholm3 validation in a multi-ethnic cohort for #ProstateCancer (SEPTA) detection: a multicentered, prospective trial. Presentation by Scott Eggener The University of Chicago. #GU24 written coverage by Rashid K. Sayyid University of Toronto > bit.ly/3uixJNc ASCO

North American validation of STHLM3 in a large diverse cohort undergoing prostate biopsy; able to maintain relative sensitivity for GG2 and higher with far superior specificity (compared to PSA)

Showing the great results from using Stockholm3 test with MRI to diagnose prostate cancer in a more effective way #stockholm3 #urology #prostatecancerdiagnosis Hari Vigneswaran, MD Henrik Grönberg sciencedirect.com/science/articl…

History repeats itself....... Prostate Cancers in the Prostate-specific Antigen Interval of 1.8–3 ng/ml: Results from the Göteborg-2 Prostate Cancer Screening Trial - European Urology europeanurology.com/article/S0302-…

Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA) out on Journal of Clinical Oncology ascopubs.org/doi/abs/10.120… The study aimed to assess the effectiveness of the Stockholm3 🇸🇪test in improving prostate cancer detection in a diverse cohort, including Asian, Black, Hispanic,

🚨Stockholm3 in a multiethnic cohort🚨 📄Journal of Clinical Oncology Compared with PSA, Stockholm3 test can 📉 unnecessary biopsies Finally, great data on a #prostatecancer biomarker from a diverse cohort (n~2k): Asian: 16% Black : 24 % Hispanic: 14% 👏 Hari Vigneswaran, MD Dr. Adam Murphy

Stockholm3 demonstrated the ability to reduce unnecessary biopsies compared with PSA across a multiethnic cohort of patients, according to data from the SEPTA trial. Hari Vigneswaran, MD #pcsm #urology urologytimes.com/view/stockholm…

🚨Correlates between PSMA PET and MRI for clinically significant #ProstateCancer 🚨 Our group just published in JNM 👉 132 tumors GG>2 from 100 pts who got both PET and MRI prior to prostatectomy UCLA Health 🗣️📢PET detects more tumors compared to MRI by:

🚨TP vs TR prostate biopsy🚨 📜TRANSLATE RCT out in The Lancet Oncology 👉Transperineal biopsy... 1⃣More ≥GG2 #prostatecancer detected 2⃣Similar to possibly fewer infections WITHOUT any antibiotic prophylaxis 🔗shorturl.at/JG0J6 👏#EAU25 Bryant_Lab Alastair Lamb

More progress on the #stockholm3 screening/confirmatory test for #prostatecancer. This one is definitely a test to watch Derya Tilki, MD #aua25

Valiant effort Ugo_Falagario to revisit the question of BCR definition comparability for RP vs. RT for #prostatecancer. Closest seems to be nadir + 0.5 for RT vs. >0.5 with PSADT <9mos for RP. I still personally want CSM outcomes for CER studies, but this is very helpful. #AUA25

Finally a marker study using PSA >1 as the threshold to move on to secondary testing for #prostatecancer. #thisistheway 🙌 Great #stockholm3 study #aua25.

On NPR this morning with Steve Inskeep Tried to give a broader view of metastatic prostate cancer landscape. npr.org/2025/05/19/nx-…

This. We see this every day. It’s how GG5 presents. Anyone saying otherwise does not treat prostate cancer.

Accurate, eloquent, and refreshingly candid by Benjamin J. Davies MD

X-torial: Cleaning up the misinformation about Joe Biden and #ProstateCancer that I am reading everywhere. The purpose of this is to provide education from someone who treats and studies PCa for a living, lead the USA National Comprehensive Cancer Network (NCCN) PCa guidelines, hold leadership in NRG Oncology National Cancer Institute

Ppl understandably bring up concerns on a population level with expanding screening in men >70yo. Let us dive into data on this. I agree with Andrew Vickers we should always do 'risk stratified' screening whether >70 or <70yo (we should not be doing PSA screening in a 50 yo